Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2019

01-11-2019 | Original Article

Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis

Authors: Massimo Mentasti, Kerry Prime, Kirsty Sands, Swati Khan, Mandy Wootton

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2019

Login to get access

Abstract

Carbapenemase-producing microorganisms are increasingly isolated and often associated with treatment failures and outbreaks. The need for reliable and timely detection and/or confirmation of carbapenemase production is paramount; therefore, a real-time PCR assay targeting IMP, NDM, VIM, KPC and OXA-48-like carbapenemases was designed and validated. All available allele variants of the above carbapenemases were downloaded from the Beta-Lactamase DataBase (http://​bldb.​eu/​), aligned with Clustal Omega and primers designed using Primer-BLAST. Real-time PCR monoplexes were optimized for the QuantStudio 6-Flex (Applied Biosystems) using the PowerUp SYBR Green Master Mix (Life Technologies) and validated using a panel of 204 characterised strains carrying a wide range of beta-lactamases, sometimes in combination. Melt-curve analysis was used to confirm positive results. The in silico approach allowed primers to be designed in conserved regions of the KPC and NDM alignments, while three primer sets for IMP and two for VIM were necessary to ensure amplification of the different variants. One primer set was designed for OXA-48-like; however, it is unlikely to detect all variants. Expected results were obtained for all 204 tested strains, with 100% sensitivity and specificity. Melt-curve analysis showed consistent Tm results for KPC, NDM, and OXA-48-like; differences were instead noted for IMP and VIM as likely consequence of higher variability in the PCR target regions. Inhibition was not observed. The assay is rapid, easy to perform and implement. It enables unequivocal detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases even when more than one type is present simultaneously.
Literature
1.
go back to reference Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297CrossRef Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297CrossRef
2.
go back to reference Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A, Wareham DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S, Hawkey PM (2018) Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem resistance evaluation surveillance trial (iCREST-UK). J Antimicrob Chemother 73(3):698–702CrossRef Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A, Wareham DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S, Hawkey PM (2018) Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem resistance evaluation surveillance trial (iCREST-UK). J Antimicrob Chemother 73(3):698–702CrossRef
3.
go back to reference Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N (2015) Dominance of international ‘high-risk clones’ among metallo-blactamase- producing Pseudomonas aeruginosa in the UK. J Antimicrob Chemother 70:103–110CrossRef Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N (2015) Dominance of international ‘high-risk clones’ among metallo-blactamase- producing Pseudomonas aeruginosa in the UK. J Antimicrob Chemother 70:103–110CrossRef
5.
go back to reference Hansen F, Hammerum AM, Skov R, Haldorsen B, Sundsfjord A, Samuelsen O (2014) Evaluation of the total MBL confirm kit (ROSCO) for detection of metallo-β-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 79(4):486–488CrossRef Hansen F, Hammerum AM, Skov R, Haldorsen B, Sundsfjord A, Samuelsen O (2014) Evaluation of the total MBL confirm kit (ROSCO) for detection of metallo-β-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 79(4):486–488CrossRef
6.
go back to reference Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 41:4623–4629CrossRef Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 41:4623–4629CrossRef
7.
go back to reference Samuelsen Ø, Buaro L, Giske CG, Simonsen GS, Aasnaes B, Sundsfjord A (2008) Evaluation of phenotypic tests for the detection of metallo-β-lactamase-producing Pseudomonas aeruginosa in a low prevalence country. J Antimicrob Chemother 61(4):827–830CrossRef Samuelsen Ø, Buaro L, Giske CG, Simonsen GS, Aasnaes B, Sundsfjord A (2008) Evaluation of phenotypic tests for the detection of metallo-β-lactamase-producing Pseudomonas aeruginosa in a low prevalence country. J Antimicrob Chemother 61(4):827–830CrossRef
11.
go back to reference Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI (2017) Beta-Lactamase DataBase (BLDB) – structure and function. J Enzyme Inhib Med Chem 32:917–919CrossRef Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI (2017) Beta-Lactamase DataBase (BLDB) – structure and function. J Enzyme Inhib Med Chem 32:917–919CrossRef
12.
go back to reference Chojnacki S, Cowley A, Lee J, Foix A, Lopez R (2017) Programmatic access to bioinformatics tools from EMBL-EBI update: 2017. Nucleic Acids Res 45(W1):W550–W553CrossRef Chojnacki S, Cowley A, Lee J, Foix A, Lopez R (2017) Programmatic access to bioinformatics tools from EMBL-EBI update: 2017. Nucleic Acids Res 45(W1):W550–W553CrossRef
13.
go back to reference Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13:134CrossRef Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13:134CrossRef
14.
go back to reference Murphy NM, McLauchlin J, Ohai C, Grant KA (2007) Construction and evaluation of a microbiological positive process internal control for PCR-based examination of food samples for Listeria monocytogenes and Salmonella enterica. Int J Food Microbiol 120:110–119CrossRef Murphy NM, McLauchlin J, Ohai C, Grant KA (2007) Construction and evaluation of a microbiological positive process internal control for PCR-based examination of food samples for Listeria monocytogenes and Salmonella enterica. Int J Food Microbiol 120:110–119CrossRef
15.
go back to reference Poirel L, Héritier C, Nordmann P (2004) Chromosome-encoded ambler class D beta-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob Agents Chemother 48:348–351CrossRef Poirel L, Héritier C, Nordmann P (2004) Chromosome-encoded ambler class D beta-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob Agents Chemother 48:348–351CrossRef
16.
go back to reference Dabos L, Jousset AB, Bonnin RA, Fortineau N, Zavala A, Retailleau P, Iorga BI, Naas T (2018) Genetic and biochemical characterization of OXA-535, a distantly related OXA-48-like β-lactamase. Antimicrob Agents Chemother 62:10 Dabos L, Jousset AB, Bonnin RA, Fortineau N, Zavala A, Retailleau P, Iorga BI, Naas T (2018) Genetic and biochemical characterization of OXA-535, a distantly related OXA-48-like β-lactamase. Antimicrob Agents Chemother 62:10
17.
go back to reference Samuelsen Ø, Hansen F, Aasnæs B, Hasman H, Lund BA, Leiros HS, Lilje B, Janice J, Jakobsen L, Littauer P, Søes LM, Holzknecht BJ, Andersen LP, Stegger M, Andersen PS, Hammerum AM (2017) Dissemination and characteristics of a novel plasmid–encoded carbapenem-hydrolyzing class D β-lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. Antimicrob Agents Chemother 62(1). doi: https://doi.org/10.1128/AAC.01260–17 Samuelsen Ø, Hansen F, Aasnæs B, Hasman H, Lund BA, Leiros HS, Lilje B, Janice J, Jakobsen L, Littauer P, Søes LM, Holzknecht BJ, Andersen LP, Stegger M, Andersen PS, Hammerum AM (2017) Dissemination and characteristics of a novel plasmid–encoded carbapenem-hydrolyzing class D β-lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. Antimicrob Agents Chemother 62(1). doi: https://​doi.​org/​10.​1128/​AAC.​01260–17
18.
go back to reference Lund M, Petersen MB, Jørgensen AL, Paulmann D, Wang M (2018) Rapid real-time PCR for the detection of IMP, NDM, VIM, KPC and OXA-48 carbapenemase genes in isolates and spiked stool samples. Diagn Microbiol Infect Dis 92:8–12CrossRef Lund M, Petersen MB, Jørgensen AL, Paulmann D, Wang M (2018) Rapid real-time PCR for the detection of IMP, NDM, VIM, KPC and OXA-48 carbapenemase genes in isolates and spiked stool samples. Diagn Microbiol Infect Dis 92:8–12CrossRef
19.
go back to reference Oueslati S, Iorga BI, Tlili L, Exilie C, Zavala A, Dortet L, Jousset AB, Bernabeu S, Bonnin RA, Naas T (2019) Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkz209 Oueslati S, Iorga BI, Tlili L, Exilie C, Zavala A, Dortet L, Jousset AB, Bernabeu S, Bonnin RA, Naas T (2019) Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother. https://​doi.​org/​10.​1093/​jac/​dkz209
20.
go back to reference Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T, Nordmann P (2015) Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828CrossRef Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T, Nordmann P (2015) Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828CrossRef
21.
go back to reference Dortet L, Naas T (2017) Noncarbapenemase OXA-48 variants (OXA-163 and OXA-405) falsely detected as carbapenemases by the β Carba test. J Clin Microbiol 55:654–655CrossRef Dortet L, Naas T (2017) Noncarbapenemase OXA-48 variants (OXA-163 and OXA-405) falsely detected as carbapenemases by the β Carba test. J Clin Microbiol 55:654–655CrossRef
Metadata
Title
Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis
Authors
Massimo Mentasti
Kerry Prime
Kirsty Sands
Swati Khan
Mandy Wootton
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-019-03637-5

Other articles of this Issue 11/2019

European Journal of Clinical Microbiology & Infectious Diseases 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine